Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects
Objective: To develop a population pharmacokinetic (PK) model for ropeginterferon alfa-2b and to compare its PK properties between Caucasian and Chinese populations.Methods: A population PK model was developed based on data from two phase I clinical trials conducted in Caucasian and Chinese individu...
Main Authors: | Min Zhu, Mei-xia Wang, Zi-ran Li, Wei Wang, Xia Su, Zheng Jiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.673492/full |
Similar Items
-
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
by: Aaron T Gerds, et al.
Published: (2023-08-01) -
Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
by: Hsien‐Hong Lin, et al.
Published: (2021-08-01) -
A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
by: Su-Yeon Bang, et al.
Published: (2023-03-01) -
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report
by: Silvio Ligia, et al.
Published: (2024-01-01) -
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
by: Albert Qin, et al.
Published: (2023-01-01)